Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
Laura Muñoz-MorenoAndrew V SchallyJuan C PrietoM José CarmenaAna M BajoPublished in: The Prostate (2018)
Taken all together, GHRH-R antagonists of the MIAMI series appear to be inhibitors of tumor progression in prostate cancer and should be considered for use in future therapeutic strategies on this malignancy.